Future studies should focus on validating our findings in preclinical animal models of CRC to assess the therapeutic potential of targeting the CYP19A1/estrogen/complex I axis and evaluate the impact of CYP19A1 modulation on tumor growth, metastasis, and chemotherapy response. Here, CYP19A1 is linked to neoplasm.